Can Gasmotin (Mosapride) and Erythromycin Be Given Concurrently?
Yes, mosapride (Gasmotin) and erythromycin can be given together safely, as there is no clinically significant interaction between these two medications despite a pharmacokinetic interaction. The combination does not cause QT prolongation or other serious cardiac adverse events 1.
Evidence for Concurrent Use
Direct Drug Interaction Study
A prospective study specifically examined the concurrent use of mosapride and erythromycin in healthy volunteers 1. The key findings were:
- Pharmacokinetic interaction exists: Erythromycin increased mosapride Cmax by 1.6-fold and prolonged its half-life from 1.6 to 2.4 hours due to CYP3A4 inhibition
- No electrocardiographic changes: Despite the pharmacokinetic interaction, there were no significant differences in QT interval or QTc between mosapride alone versus concurrent use with erythromycin
- No correlation between drug levels and cardiac effects: Plasma mosapride concentrations did not correlate with any ECG parameters
- No cases of QTc prolongation: All QTc values remained within normal limits
This is clinically important because both drugs have theoretical concerns for cardiac effects, yet the actual combination proved safe.
Clinical Context from Guidelines
Erythromycin Use in Gastroparesis
The 2025 AGA guidelines provide important context for erythromycin use 2:
- Low-dose erythromycin (40-150 mg before meals) is recommended for gastroparesis as a prokinetic agent
- Safety concerns include: QT-prolongation, drug interactions (CYP3A inhibitor), and antibiotic resistance
- Drug holidays recommended: 3 weeks on therapy, 1 week off to prevent tachyphylaxis
Combination Prokinetic Therapy
The 2019 ESPEN ICU guidelines explicitly support combination prokinetic therapy 3:
- Metoclopramide and erythromycin can be used together as prokinetic therapy (Grade 0 recommendation, 100% consensus)
- This establishes precedent that erythromycin can be safely combined with other prokinetic agents
Important Caveats
Monitor for QT Prolongation Risk Factors
While the combination is safe, both drugs individually carry QT prolongation warnings 4:
Erythromycin QT risk factors:
- Hypokalaemia or hypomagnesemia
- Pre-existing cardiac conditions
- Concurrent use of other QT-prolonging drugs
- Elderly patients
If combining these medications:
- Check baseline ECG if patient has cardiac risk factors
- Correct electrolyte abnormalities (potassium, magnesium)
- Avoid adding other QT-prolonging medications (e.g., domperidone, metoclopramide, moxifloxacin) 5
Erythromycin Drug Interactions
Erythromycin is a CYP3A4 inhibitor 4, which explains the mosapride interaction. Be aware of:
- Increased levels of other CYP3A4 substrates (statins, benzodiazepines, calcium channel blockers)
- Enhanced anticoagulant effects with warfarin
- Digoxin level elevation
Duration of Therapy
- Erythromycin: Use for short courses (24-48 hours to 2-4 days) to minimize tachyphylaxis and antibiotic resistance 3
- Mosapride: Can be used for longer-term management of gastroparesis or functional dyspepsia 6
Practical Recommendation
The combination is safe to use concurrently without dose adjustment. The pharmacokinetic interaction (increased mosapride levels) does not translate into clinical harm. However, maintain vigilance for the individual side effects of each medication, particularly cardiac monitoring in high-risk patients.